- Home
- TLRY vs RGNX Comparison
TLRY vs RGNX Comparison
Compare TLRY & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TLRY | RGNX |
|---|---|---|
| Founded | N/A | 2008 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 570.4M | 528.6M |
| IPO Year | 2018 | 2015 |
Fundamental Metrics
Financial Performance| Metric | TLRY | RGNX |
|---|---|---|
| Price | $3.91 | $9.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $72.33 | $28.75 |
| AVG Volume (30 Days) | ★ 3.5M | 2.5M |
| Earning Date | 04-01-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.08 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,393,000.00 |
| Revenue This Year | $8.79 | $51.21 |
| Revenue Next Year | $19.98 | $19.08 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 126.48 |
| 52 Week Low | $0.55 | $5.46 |
| 52 Week High | $15.70 | $16.19 |
Technical Indicators
Market Signals| Indicator | TLRY | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 22.50 | 41.84 |
| Support Level | $0.77 | $9.51 |
| Resistance Level | $4.85 | $10.16 |
| Average True Range (ATR) | 0.18 | 1.04 |
| MACD | -0.02 | -0.56 |
| Stochastic Oscillator | 3.18 | 17.69 |
Price Performance
Historical ComparisonAbout TLRY Tilray Brands Inc.
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure comes mainly from alcohol.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.